| 噻唑烷二酮类药物临床安全性评价 |
| |
| 引用本文： | 杨义生.噻唑烷二酮类药物临床安全性评价[J].世界临床药物,2008,29(11):641-646. |
| |
| 作者姓名： | 杨义生 |
| |
| 作者单位： | 美国贝勒医学院内分泌糖尿病系 |
| |
| 摘 要： | 噻唑烷二酮类药物(TZD)是一类新型口服降糖药,主要通过激活过氧化物酶体增生物激活受体γ(PPARγ)增强胰岛素敏感性.临床资料一致表明,这类药物中的罗格列酮和吡格列酮均可显著增加心力衰竭风险.资料显示,罗格列酮可能增加缺血性心脏病变包括心肌梗死(MI)的发病风险,虽然该绝对风险极低,但吡格列酮则不增加该风险.此外,TZD可抑制骨形成,加速骨丢失,增加女性2型糖尿病患者四肢骨折风险.本文总结近年来已完成或正在进行的以及荟萃分析的TZD相关的临床研究结果,以期对TZD的临床安全性进行客观评估.
|
| 关 键 词： | 噻唑烷二酮类药物 安全性 心力衰竭 心肌梗死 骨密度 |
The clinical safety evaluation of thiazolidinediones |
| |
| YANG Yi-Sheng.The clinical safety evaluation of thiazolidinediones[J].WORLD CLINICAL DRUGS,2008,29(11):641-646. |
| |
| Authors: | YANG Yi-Sheng |
| |
| Institution: | YANG Yi-Sheng(Section of Endocrinology , Diabetes,Department of Medicine,Baylor College of Medicine,Houston,TX 77030,US) |
| |
| Abstract: | Thiazolidinediones(TZDs) are agonists of the peroxisome proliferator-activated receptor gamma which improve glycaemic control by reducing insulin resistance.Data from clinical trials consistently indicate that treatment with TZDs(both rosiglitazone and pioglitazone) significantly increase the risk of heart failure.Rosiglitazone, but not pioglitazone, is associated with an increased risk of myocardial ischemic events including myocardial infarction(MI), although the absolute magnitude is extremely small.In a... |
| |
| Keywords: | thiazolidinediones safety heart failure myocardial infarction bone density |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
